MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Cancer Immunotherapy and Biomarkers
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,980 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,980 works in the cohort · of 4,299,418page 4 of 60

Labels cover 12 of 2,980 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,980 of 2,980 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +15 more
2024· article· en· The Lancet· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
243
citations
afffundunlabeled
Pembrolizumab
Leila Khoja, Marcus O. Butler, Soonmo Peter Kang, Scot Ebbinghaus, Anthony M. Joshua
2015· review· id· Journal for ImmunoTherapy of Cancer· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
222
citations
affno abstractunlabeled
Targeting co-stimulatory molecules in autoimmune disease
Natalie M. Edner, Gianluca Carlesso, James S. Rush, Lucy S. K. Walker
2020· review· en· Nature Reviews Drug Discovery· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
222
citations
affunlabeled
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Khashayar Esfahani, Najwa Buhlaiga, Paméla Thébault, Réjean Lapointe, Nathalie A. Johnson, Wilson H. Miller
2019· letter· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
220
citations
affno abstractunlabeled
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Leśniewski-Kmak +15 more
2019· article· en· European Journal of Cancer· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
217
citations
afffundunlabeled
The Tumor Immune Contexture of Prostate Cancer
Natasha Vitkin, Sarah Nersesian, D. Robert Siemens, Madhuri Koti
2019· review· en· Frontiers in Immunology· Medicine
distilled prediction:candidate · noneconsensus · none
217
citations
affno abstractunlabeled
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina Chiara Garassino, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Manuel Dómine +13 more
2020· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
213
citations

How this was built: Screen · Findings · About